Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.

about

(Immuno)proteasomes as therapeutic target in acute leukemia.

P2860

Q47131929-5ACA1C64-6635-4F2E-A032-0D0441A8D3FF

P2860

Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.

Item

http://www.wikidata.org/entity/Q41996298

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pharmacodynamic monitoring of ...... pus nephritis and myocarditis.

@en

type

Item

label

Pharmacodynamic monitoring of ...... pus nephritis and myocarditis.

@en

prefLabel

Pharmacodynamic monitoring of ...... pus nephritis and myocarditis.

@en

P1476

Pharmacodynamic monitoring of ...... pus nephritis and myocarditis.

@en

P2093

Alexandre E Voskuyl

http://www.w3.org/2001/XMLSchema#string

Denise Niewerth

http://www.w3.org/2001/XMLSchema#string

Gerrit Jansen

http://www.w3.org/2001/XMLSchema#string

Hans W M Niessen

http://www.w3.org/2001/XMLSchema#string

Jacqueline Cloos

http://www.w3.org/2001/XMLSchema#string

Jonathan L Blank

http://www.w3.org/2001/XMLSchema#string

Joost W van der Heijden

http://www.w3.org/2001/XMLSchema#string

Karina A de Groot

http://www.w3.org/2001/XMLSchema#string

Michel Tsang A Sjoe

http://www.w3.org/2001/XMLSchema#string

Sonja Zweegman

http://www.w3.org/2001/XMLSchema#string

P2860

Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 T-cells and IFNΓ

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.

Proteasome inhibitors in multiple myeloma: 10 years later.

Systemic lupus erythematosus in 2013. Taking a closer look at biologic therapy for SLE.

Proteasome inhibitors as experimental therapeutics of autoimmune diseases.

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.

Expression of proteasomal immunosubunit beta1i is dysregulated in inflammatory infiltrates of minor salivary glands in Sjogren's syndrome.

The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.

P304

e000121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/LUPUS-2015-000121

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287419777

http://www.w3.org/2001/XMLSchema#string

P698

26719810

http://www.w3.org/2001/XMLSchema#string

P932

4691954

http://www.w3.org/2001/XMLSchema#string

Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.

about

P2860

P2860

Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932